At Nuvie Bio, we are developing next generation migraine treatments designed to deliver an unprecedented combination of speed to relief, and high and consistent efficacy with enhanced safety and tolerability that will enable patients to quickly resume their lives.
Leveraging our proprietary peptide technology, we are creating a new class of migraine medication designed to reduce migraine burden in previously unattainable ways.
Our Commitment
Nuvie Bio is committed to improving the lives of millions of people with migraine. Despite recent advancements, there are still significant persistent unmet medical needs for the acute treatment of migraine.
Migraine is a highly prevalent and disabling neurological disease. Currently, patients and providers must choose between higher efficacy or better tolerability for acute treatment, since no medication offers both simultaneously.
1, 2, 3, 4
Our Science
At Nuvie Bio, we are targeting the clinically validated calcitonin gene-related peptide (CGRP) receptor in unprecedented ways to create transformative products.
We are developing the first rapidly absorbed subcutaneous CGRP receptor antagonist, with the goal of providing rapid relief from migraine to millions of people who are not satisfied with existing therapies.
NVI-100* is a first-in-class water-soluble peptide CGRP receptor antagonist, specifically engineered to enable the design of a low volume subcutaneous formulation, administered via a patient-friendly autoinjector. NVI-100 is projected to deliver a never before achieved combination of speed to relief and high and consistent efficacy, along with minimal adverse events. Because it is primarily cleared by the kidney, NVI-100 is also expected to reduce the potential for drug-drug interactions, enhancing tolerability, unlike drugs that are metabolized by the liver.
References
-
Imitrex (sumatriptan) Injection Full Prescribing Information. GSK. 02/2023
-
Imitrex (sumatriptan) Tablets Full Prescribing Information. GSK. 02/2024
-
Ubrelvy (ubrogepant) Tablets Full Prescribing Information. AbbVie. 02/2023
-
Nurtec ODT (rimegepant) Orally Disintegrating Tablets Full Prescribing Information. Pfizer. 12/2021
* Disclaimer: None of our product candidates has been approved by any regulatory authority or deemed safe or effective for any indication. Information about our product candidates are subject to change based on ongoing testing.